BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AtheroGenics (AGIX) Noteholders Expect Company Will Elect Not to Pay 2008 Notes When Due


9/2/2008 9:09:25 AM

ATLANTA--(BUSINESS WIRE)--CNH Partners, LLC, Tamalpais Asset Management LP, Tang Capital Partners, LP, and Zazove Associates LLC (the “08 Noteholders”), which collectively hold approximately 96% of the outstanding 4 ½ % Convertible Notes Due 2008 (the “08 Notes”) issued by AtheroGenics, Inc. (“AtheroGenics”), today announced that they expect, based on conversations with representatives of AtheroGenics, that AtheroGenics will elect not to repay their debt under the 08 Notes. The 08 Notes mature today, September 2, 2008, and the principal amount of approximately $30.5 million is due and payable. According to AtheroGenic’s latest Quarterly Report on Form 10-Q, AtheroGenics had approximately $66.2 million in cash, cash equivalents, and short term investments as of June 30, 2008. Moreover, the 08 Noteholders believe additional funds are available at market terms to fund ongoing operations, including from the 08 Noteholders, although the 08 Noteholders are not aware that AtheroGenics has made any attempt to secure such financing.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES